RESULTS OF EXTENDED PELVIS LYMPHADENECTOMY IN RADICAL CYSTECTOMY PATIENTS FOR TREATMENT INVASIVE BLADDER CANCER

2017 ◽  
pp. 95-100
Author(s):  
Luong Vinh Le ◽  
Van Tung Hoang ◽  
Ngoc khanh Tran ◽  
Thanh Liem Ngo ◽  
Dinh khanh Le
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Radical Cystectomy ◽  
Pelvic Lymphadenectomy ◽  
Invasive Bladder Cancer ◽  
Postoperative Survival ◽  
Lymph Node Count ◽  
Node Positive ◽  
Lymph Node Positive ◽  
Centre Hospital

Background: For long time the standard lymphadenectomy is the part of radical cystectomy surgery for treament invasive bladder cancer. Some new research show the good result of extended pelvic lymphadenectomy in improving postoperative survival. Purpose: Report techniques and results of extended pelvic lymphadenectomy in radical cystectomy for invasive bladder cancer. Material and method: Prospective descriptive study on 38 extended pelvic lymphadenectomy patients from January 2013 to April 2017 at Hue Centre Hospital. Results: Mean of age: 63.45 ± 12.5 years old. Female/man: 3/38. Lymph nodes metastasis6/38 patients, 4 obturator lymph node positive and 2common iliac vessels lymph node positive. Mean time of pelvic lymphadenectomy: 78 ± 43 mins. Mean of blood loss: 120 ± 55ml. Mean of lymph node count: 13 ± 4. Conclusion: Extended pelvic lymphadenectomy should be perform for all patients radical cystectomy to improve postoperative survival and It is safe when perform at a good surgery centre with experienced surgeon. Key words: Extended pelvic lymphadenectomy; invasive bladder cancer; Radical cystectomy

scholarly journals THE CLINICAL STUDY OF RADICAL CYSTECTOMY FOR LYMPH NODE POSITIVE BLADDER CANCER

1997 ◽  
Vol 88 (12) ◽  
pp. 992-996 ◽  
Author(s):  
Takahiro Kajiwara ◽  
Keishi Kashibuchi ◽  
Mitsuru Shinohara ◽  
Akio Munakata ◽  
Hironao Itakura ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Clinical Study ◽  
Radical Cystectomy ◽  
Node Positive ◽  
Lymph Node Positive

1899 LYMPH NODE POSITIVE BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND LYMPHADENECTOMY: EFFECT OF THE LEVEL OF NODE POSITIVITY

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Tatum Tarin ◽  
Nicholas Power ◽  
Behfar Ehdaie ◽  
John Sfakianos ◽  
Jonathan Silberstein ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Radical Cystectomy ◽  
Node Positive ◽  
Lymph Node Positive

Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy

2014 ◽  
Vol 113 (4) ◽  
pp. 554-560 ◽  
Author(s):  
Pascal Zehnder ◽  
Urs E. Studer ◽  
Siamak Daneshmand ◽  
Frédéric D. Birkhäuser ◽  
Eila C. Skinner ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Extended Lymphadenectomy ◽  
Node Positive ◽  
Lymph Node Positive

Adjuvant chemotherapy in lymph node positive bladder cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15526-15526
Author(s):  
O. N. Gofrit ◽  
W. M. Stadler ◽  
K. C. Zorn ◽  
J. Silvestre ◽  
A. L. Shalhav ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Systemic Disease ◽  
Performance Status ◽  
Real Life ◽  
Hazard Ratio ◽  
Node Positive ◽  
Lymph Node Positive

15526 Background: Lymph node-positive bladder cancer is a systemic disease in the majority of patients. Prescribing adjuvant chemotherapy shortly after surgery, when tumor burden is low seems reasonable, yet there is no proof that this treatment strategy improves survival. In this retrospective study, we compared the outcomes of patients with microscopic lymph node positive bladder cancer (pN1 or pN2) treated with radical cystectomy followed by adjuvant chemotherapy and those who declined chemotherapy. Methods: Sixty-seven patients with lymph node positive bladder cancer (pN1 in 26 patients and pN2 in 41) who underwent radical cystectomy between April 1995 and April 2005 were reviewed. Combined adjuvant chemotherapy (gemcitabine and cisplatin in most patients) was given to 35 patients (52%), but deferred by 32 (48%). The two groups were similar in performance status, postoperative complication rate and N stage but deferring patients were on average 4 years older and had a more advanced T stage. Results: Adjuvant chemotherapy was well tolerated with 28/35 patients (80%) completed all 4 cycles. Median overall survival of patients given adjuvant chemotherapy was 48 months compared to 8 months for deferring patients (hazard ratio 0.13, 95% CI 0.04–0.4, p<0.0001). Multivariate age adjusted analysis showed that adjuvant chemotherapy was an independent factor affecting overall survivals (hazard ratio 0.2, p<0.0001). Subgroup analysis demonstrated that chemotherapy provided survival benefit for patients with pN2 disease but not for patients with pN1 disease (p=0.0001 and p=0.235 respectively). Conclusions: This retrospective real-life study supports the use of adjuvant chemotherapy after radical cystectomy in patients with node positive bladder cancer, especially when more than one lymph node is involved. No significant financial relationships to disclose.

scholarly journals A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0174039 ◽  
Author(s):  
Kim E. M. van Kessel ◽  
Harmen J. G. van de Werken ◽  
Irene Lurkin ◽  
Angelique C. J. Ziel – van der Made ◽  
Ellen C. Zwarthoff ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bladder Cancer ◽  
Lymph Node ◽  
Radical Cystectomy ◽  
Gene Expression Signature ◽  
Muscle Invasive Bladder Cancer ◽  
Node Positive ◽  
Node Positive Disease ◽  
Lymph Node Positive ◽  
Muscle Invasive

scholarly journals The Influence of Lymph Node Count on Oncological Outcome of Radical Cystectomy in Chemotherapy Pre-Treated and Chemotherapy-Naïve Patients with Muscle Invasive Bladder Cancer

2021 ◽  
Vol 10 (21) ◽  
pp. 4923
Author(s):  
Artur Lemiński ◽  
Krystian Kaczmarek ◽  
Wojciech Michalski ◽  
Bartosz Małkiewicz ◽  
Katarzyna Kotfis ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Radical Cystectomy ◽  
Oncological Outcome ◽  
Standard Of Care ◽  
Invasive Bladder Cancer ◽  
Study Cohort ◽  
Muscle Invasive Bladder Cancer ◽  
Lymph Node Count ◽  
Muscle Invasive

Radical cystectomy (RC) with pelvic lymph node dissection (PLND) remains the mainstay of treatment for muscle-invasive bladder cancer (MIBC). The extent of PLND and number of removed lymph nodes (LNs) have been associated with improved staging and survival outcomes in several series of RC patients. Neoadjuvant chemotherapy (NAC) has become standard of care for cisplatin-eligible patients qualified to RC, yet few studies on PLND stratified cases according to the receipt of NAC. We aimed to address this issue and reevaluate the prognostic value of PLND nodal yields in series of patients who underwent RC on the verge of the NAC era. This single-center, retrospective, clinical follow-up study enrolled 439 consecutive patients, out of whom 83 received NAC. We analyzed survival outcome of RC according to the number of removed nodes between NAC and non-NAC subgroups. We found PLND thresholds of 10 and 15 LNs prognostically meaningful in our study cohort, and this association was particularly pronounced in the non-NAC subgroup. Higher numbers of LNs provided a 25% reduction in risk of all-cause mortality and correspondingly correlated with up to a 14% increase in 3-year overall survival. The receipt of NAC diminished the benefit of adequate PLND, as the number of retrieved LNs was not associated with survival in the NAC-RC cohort. Given the limitations of our study, additional research is needed to verify these findings.

Sign in / Sign up

Export Citation Format

Share Document